Yuichi Sugiyama - Nanotechnology

Author Information

Yuichi Sugiyama is a distinguished researcher affiliated with the Sugiyama Laboratory at the RIKEN Baton Zone Program, RIKEN Cluster for Science, Technology and Innovation Hub, located in Yokohama, Kanagawa, Japan. His work focuses on the domains of drug metabolism and pharmacokinetics, with a particular emphasis on the mechanisms of drug transport and the modeling of drug interactions.

Research Contributions

Yuichi Sugiyama has made significant contributions to the field of pharmacokinetics and drug transport. His research encompasses the study of organic anion transporting polypeptides (OATPs), hepatobiliary transporters, and the impact of drug interactions on these transport mechanisms. Notable recent works include the clinical evaluation of [18F]pitavastatin, the effects of cyclosporine A on OATP1B1 and OATP1B3 substrates, and physiologically based pharmacokinetic (PBPK) modeling. His studies are instrumental in bridging the gap between in vitro and in vivo hepatic uptake clearances and improving predictions of drug-drug interactions.

Aliases

Y Sugiyama, Y. Sugiyama, Yuichi Sugiyama

Publication and Citation Metrics

Metric	Value
Total Papers	916
Total Citations	47,835
h-index	110

Publications:

Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity.

DOI: 10.1016/j.dmpk.2022.100449

Year: 2022

Experimental and modeling evidence supporting the trans-inhibition mechanism for preincubation time-dependent, long-lasting inhibition of organic anion transporting polypeptide (OATP) 1B1 by cyclosporine A.

DOI: 10.1124/dmd.121.000783

Year: 2022

Effect of cyclosporin A and impact of dose staggering on OATP1B1/1B3 endogenous substrates and drug probes for assessing clinical drug interactions.

DOI: 10.1002/cpt.2584

Year: 2022

Physiologically Based Pharmacokinetic/Pharmacodynamic Model for the Treatment of Dengue Infections Applied to the Broad Spectrum Antiviral Soraphen A.

DOI: 10.1021/acsptsci.1c00078

Year: 2021

Revisiting Nonlinear Bosentan Pharmacokinetics by Physiologically Based Pharmacokinetic Modeling: Target Binding, Albeit Not a Major Contributor to Nonlinearity, Can Offer Prediction of Target Occupancy

DOI: 10.1124/dmd.120.000023

Year: 2021

Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: Bridging the gap of hepatic uptake clearance between in vitro and in vivo.

DOI: 10.1016/j.pharmthera.2021.107938

Year: 2021

Post-translational regulation of the major drug transporters in the families of organic anion transporters and organic anion-transporting polypeptides.

DOI: 10.1074/jbc.REV120.009132

Year: 2020

Improved prediction of the drug-drug interactions of pemafibrate caused by cyclosporine A and rifampicin via PBPK modeling: Consideration of the albumin-mediated hepatic uptake of pemafibrate and inhibition constants with preincubation against OATP1B.

DOI: 10.1016/j.xphs.2020.10.016

Year: 2020

Evaluation of hepatic uptake of OATP1B substrates by short term-cultured plated human hepatocytes: Comparison with isolated suspended hepatocytes.

DOI: 10.1016/j.xphs.2020.10.041

Year: 2020

Transient, tunable expression of NTCP and BSEP in MDCKII cells for kinetic delineation of the rate-determining process and inhibitory effects of rifampicin in hepatobiliary transport of taurocholate.

DOI: 10.1016/j.xphs.2020.10.064

Year: 2020

What are Magnetic Nanocomposites?

What About Regulatory and Compliance Costs?

How Can These Hazards Be Managed?

What Role Do Nano-Lubricants Play?

How Does Nanoscale FTIR Work?

How does Nanotechnology influence Electrical Circuits?

How Does Nanotechnology Aid Organ Transplants?

What Are the Benefits of Using Nanotechnology in OSCs?

What are the Challenges Associated with Diffraction in Nanotechnology?

What is Tissue Retention in Nanotechnology?

Partnered Content Networks

Relevant Topics